Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up

Lau, Abby; Strebe, Joslyn K.; Sura, Teena; Hansen, Laura A.; Jain, Mamta

doi:10.1002/hsr2.645

Cited by 2 publications

(1 citation statement)

References 42 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent analysis of the hepatitis C treatment cascade in the US found that those who injected drugs or used other illicit substances in the past 6 months were less likely to initiate HCV treatment [43], and an analysis of adult HIV/HCV co-infected patients in the DAA era in the Netherlands found lower proportions of those who injected drugs initiating HCV treatment [45]. Among a PLHIV cohort in Israel, drug use was also found to be associated with reduced access to HCV treatment [46] and active injection drug use was associated with reduced odds of linkage to HCV care among PLHIV in the US [47]. Whilst the association between injecting drug use and reduced odds of HCV treatment initiation or linkage is likely a reflection of the various socio-economic, health system, and policy factors that contribute to reduced access to health services among PWID, it is important to note the substantial research showing that PWID achieve good HCV cascade outcomes, including adherence to treatment, low discontinuation rates, and high SVR rates [48][49][50].…”

Section: Plos Onementioning

confidence: 99%

Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020

Ross¹,

Rupasinghe²,

Avihingsanon³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Chronic hepatitis C virus (HCV) infection contributes to substantial morbidity and mortality among adults living with HIV. Cascades of HCV care support monitoring of program performance, but data from Asia are limited. We assessed regional HCV coinfection and cascade outcomes among adults living with HIV in care from 2010–2020. Methods Patients ≥18 years old with confirmed HIV infection on antiretroviral therapy (ART) at 11 clinical sites in Cambodia, China, India, Indonesia, South Korea, Thailand and Vietnam were included. HCV- and HIV-related treatment and laboratory data were collected from those with a positive HCV antibody (anti-HCV) test after January 2010. An HCV cascade was evaluated, including proportions positive for anti-HCV, tested for HCV RNA or HCV core antigen (HCVcAg), initiated on HCV treatment, and achieved sustained virologic response (SVR). Factors associated with screening uptake, treatment initiation, and treatment response were analyzed using Fine and Gray’s competing risk regression model. Results Of 24,421 patients, 9169 (38%) had an anti-HCV test, and 971 (11%) had a positive result. The proportion with positive anti-HCV was 12.1% in 2010–2014, 3.9% in 2015–2017, and 3.8% in 2018–2020. From 2010 to 2014, 34% with positive anti-HCV had subsequent HCV RNA or HCVcAg testing, 66% initiated HCV treatment, and 83% achieved SVR. From 2015 to 2017, 69% with positive anti-HCV had subsequent HCV RNA or HCVcAg testing, 59% initiated HCV treatment, and 88% achieved SVR. From 2018 to 2020, 80% had subsequent HCV RNA or HCVcAg testing, 61% initiated HCV treatment, and 96% achieved SVR. Having chronic HCV in later calendar years and in high-income countries were associated with increased screening, treatment initiation or achieving SVR. Older age, injecting drug use HIV exposure, lower CD4 and higher HIV RNA were associated with reduced HCV screening or treatment initiation. Conclusions Our analysis identified persistent gaps in the HCV cascade of care, highlighting the need for focused efforts to strengthen chronic HCV screening, treatment initiation, and monitoring among adult PLHIV in the Asia region.

show abstract